BioSpace News Archive

RadNet, Inc. announced that it will host a conference call to discuss its first quarter 2022 financial results on Monday, May 9th, 2022 at 7:30 a.m. Pacific Time.

Insulet Corporation presented new Omnipod® 5 Automated Insulin Delivery System study results in type 2 diabetes and other clinical data in type 1 diabetes at the Advanced Technologies & Treatments for Diabetes conference in Barcelona, Spain, and online.

AcureX Therapeutics Corporation, a privately-held preclinical-stage biopharmaceutical company focused on developing potential disease altering therapeutics for neurodegenerative diseases, announced that it was selected to receive a grant from The Michael J. Fox Foundation to accelerate the development of AcureX’s biomarker for use in Parkinson’s disease drug development and clinical trials.

BeiGene announced the Independent Data Monitoring Committee determined at a pre-planned interim analysis that RATIONALE 306, a global Phase 3 trial of tislelizumab in combination with chemotherapy, had met the study’s primary endpoint of overall survival in patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma.

Pyxis Oncology, Inc. announced that Lara Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 2:40 p.m. PT in Las Vegas, Nevada.

Acutus Medical, Inc. announced a commitment letter from Deerfield Management Company, to refinance its existing debt with a new longer-term credit facility, and in conjunction with the refinancing, a definitive agreement to sell the Company’s left-heart access portfolio to Medtronic.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced the appointment of Mr. LiongHo Chua as President of Greater China.

Boston Scientific Corporation generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.

Xenetic Biosciences, Inc. announced that it has entered into exclusive license and sublicense agreements with CLS Therapeutics to develop its interventional DNase based oncology platform, which is aimed at improving outcomes of existing treatments, including immunotherapies.

Zomedica Corp. announced that Larry Heaton, Chief Executive Officer, will provide a strategic update and discuss first quarter 2022 earnings at the upcoming H.C. Wainwright Global Investment Conference, scheduled for 11:30 am ET on May 24, 2022.